NCT03115996View on ClinicalTrials.gov

Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN3918 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

May 10, 2017

Primary Completion Date

August 31, 2018

Study Completion Date

August 31, 2018

Conditions
Healthy Volunteers
Interventions
DRUG

REGN3918

Intravenous (IV) or Subcutaneous (SC)

DRUG

Placebo

Matching Placebo

Trial Locations (1)

LS2 9LH

Covance Clinical Research Unit (CRU) Ltd., Leeds

All Listed Sponsors
lead

Regeneron Pharmaceuticals

INDUSTRY

NCT03115996 - Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN3918 in Healthy Volunteers | Biotech Hunter | Biotech Hunter